|
 |
| home > ebr > autumn 2003 > primary production of biopharmaceuticals in plants - an economically attractive choice? |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
The progress of molecular plant genetics, and particularly of transgene expression in plants, has spurred the interest of academia and companies to consider them as eukaryotic hosts for biopharmaceutical production and as an additional or even alternative system to established mammalian cell culture (CHO) and yeast fermentation (1). Two arguments favouring plant hosts have frequently been quoted, namely safety - the absence of adventitious mammalian viral or prionic contamination - and the unlimited scalability of production.
Whether the future launch of biogenerics and the market introduction of numerous new therapeutic monoclonal antibodies will really be accompanied by a strong capacity shortage in primary production, as often predicted, is as yet uncertain. Therefore it is worthwhile to analyse whether plant expression systems have the potential to become an additional sourcing route for biopharmaceutical active ingredients in collaboration with, and as a feasible technological extension of, established mammalian cell culture and microbial fermentation.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
News and Press Releases |
 |
Ultra slim and ultra quick
More info >>
|
|
|
